Cohance Lifesciences Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.

Revenue declinedEBITDA margin compressionResults restatedExceptional itemResults View source PDF Explain this filing

COHANCE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-11.4%Reaction day

₹352.00

prior close

₹320.50

announcement price

After-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)-1.6%-9.8% vs market

Pharmaceuticals peers, median of 156sector-0.9%-10.5% vs sector

On the reaction day the stock moved 9.8 pts less than Nifty Smallcap 250 and 10.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.0

10m

+1.3

15m

+0.7

30m

+0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-11.4-1.6-9.8-0.9-10.5

Next day

-13.1-1.7-11.4-1.4-11.7

-12.2-0.9-11.3-0.9-11.3

-7.8-0.4-7.4-0.5-7.4

-10.9-1.6-9.3-2.0-8.9

-13.1-1.8-11.3-2.2-10.9

-11.9-2.0-9.9-2.8-9.1

15d

-19.3-7.3-12.0-6.9-12.4

-15.3-8.6-6.7-8.6-6.7

+1.7-3.5+5.2-3.5+5.2

+29.8+3.3+26.5+0.8+29.0

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 156Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Cohance Lifesciences (formerly Suven Pharmaceuticals) reported weak Q3 and 9M FY26 results on February 12, 2026. Consolidated revenue for 9MFY26 declined 6.7% year-on-year to ₹1,649 crore, while Q3FY26 revenue fell 19.5% to ₹545 crore. Adjusted EBITDA for 9MFY26 dropped 43% to ₹348 crore with margins compressing to 21.1%, and Q3 Adjusted EBITDA fell 68% to ₹85 crore (margin of 15.6%). Standalone Q3 PAT was ₹47 crore versus ₹154 crore in the year-ago quarter. The company blamed customer inventory adjustments, biotech funding weakness, and delayed reorders, plus a Warning Letter at its Nacharam facility that deferred ~₹55 crore of shipments. Exceptional items of ₹13 crore were booked for new labour codes and merger-related restructuring. Positively, gross margins expanded ~200 bps to 72.8%, the company generated ₹175 crore of free cash flow, and held ₹432 crore in cash with a net cash position of ₹176 crore.

Likely market impact

Near-term results are clearly weak, with revenue and EBITDA both sharply lower, and management has cut FY26 revenue guidance to an early-to-mid double-digit decline, which is likely to weigh on the stock. However, management expects a return to growth in FY27 as customer reorders resume, commercial pipeline conversions progress, and the US ADC facility comes online, which could limit the downside for longer-term investors.